The United States Food and Drug Administration (FDA) has granted Priority Review for spesolimab for the treatment of flares in patients with generalized pustular psoriasis (GPP), a rare and life-threatening skin disease. If approved, spesolimab would become the first FDA-approved treatment for GPP flares. In clinical trials, spesolimab demonstrated rapid clearance of pustules in adult patients with GPP experiencing a flare. Additionally, the FDA also granted Breakthrough Therapy Designation for spesolimab in the treatment of GPP flares.
Read the full press release to learn more.
Tags: spesolimab, generalized pustular psoraisis, gpp, fda